Kiniksa Pharmaceuticals (KNSA) AI Stock Analysis

• Market Cap: $2.11B
• Dividend Yield: N/A
• Average Volume (3M): 598.87K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: 59.45%
• EPS Growth: -290.38%
• Country: US
• Employees: 315
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 0.11
• Shares Outstanding: 42,336,227
• 10 Day Avg. Volume: 597,402
• 30 Day Avg. Volume: 598,867
• PEG Ratio: -1.92
• Price to Book (P/B): 4.39
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 46.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $38.50
• Price Target Upside: 30.42% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 75 Outperform
• Price Target: $32.00 ▲(8.40%Upside)

Kiniksa Pharmaceuticals is showing strong financial and operational performance, bolstered by robust technical momentum and positive earnings call insights. The company's improving cash flow and strategic advancements in its product pipeline are strengths, though valuation challenges due to unprofitability and lack of dividends weigh on the overall score.

Positive Factors

Financial Health

Kiniksa Pharmaceuticals ended the year with $243.6 million of cash and equivalents and expects to be cash flow positive while funding clinical trials, indicating strong financial health.

Market Share Growth

Arcalyst market share should continue to grow in earlier lines of treatment, with encouraging trends in expected utilization in 1st and 2nd recurrence points.

Product Development

Management highlighted KPL-387, a new, wholly owned IL-1R1-targeting monoclonal antibody for recurrent pericarditis which could potentially be administered as subcutaneous injection in liquid formulation and dosed monthly.

Negative Factors

Clinical Pipeline

The lack of clinical catalysts in 2025 means Arcalyst will be the main driver of the stock in the near term.

Product Discontinuation

The company announced the discontinuation of its abiprubart development plans in Sjögren’s disease, which is viewed as a rational decision given the competitive landscape.

Kiniksa Pharmaceuticals Business Overview & Revenue Model

Company Description

Kiniksa Pharmaceuticals (KNSA) is a biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutic medicines for patients with debilitating diseases with significant unmet medical needs. The company's core products are primarily in the fields of immunology, inflammation, and autoimmunity, with a pipeline that includes both clinical and preclinical stage product candidates.

How the Company Makes Money

Kiniksa Pharmaceuticals makes money primarily through the development and commercialization of its proprietary drug products. The company generates revenue through sales of its approved therapies, licensing agreements, and strategic collaborations with other pharmaceutical companies. These partnerships may include co-development and co-commercialization agreements, which provide Kiniksa with milestone payments and royalties based on sales achievements. Additionally, the company may engage in research collaborations that offer funding to advance its clinical programs and further enhance its product pipeline.

Kiniksa Pharmaceuticals Financial Statement Overview

Summary

Kiniksa Pharmaceuticals is showing robust revenue growth and a strong gross profit margin. The company has significantly reduced its net loss, indicating progress towards profitability. The balance sheet is stable with low leverage, and cash flow metrics are strong, suggesting efficient cash management and operational efficiency. However, past financial instability is still a consideration.

Income Statement

Kiniksa Pharmaceuticals has shown impressive revenue growth, with significant increases over the past few years, including a 13.7% growth from 2024 to 2025 TTM. Gross profit margin is strong at approximately 93.8% in the TTM period. However, the company is still operating at a net loss, though it has improved significantly from previous years, reducing the net loss from $43.19 million in 2024 to $2.9 million in the TTM period. This indicates a positive trajectory towards profitability.

Balance Sheet

The balance sheet shows a healthy equity position with stockholders' equity growing to $457.49 million. The debt-to-equity ratio is low at approximately 0.02, indicating low leverage and reduced financial risk. However, the company's equity ratio of 76.3% highlights stability, but the historical negative equity in 2021 and prior years is a concern, pointing to past financial instability.

Cash Flow

Cash flow analysis reveals positive trends with free cash flow growing by 72% from 2024 to the TTM period. The operating cash flow to net income ratio is exceptionally strong, indicating efficient cash management. Free cash flow to net income ratio also reflects a robust cash-generating ability. These metrics suggest strong operational efficiency and cash management.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
481.17M	423.24M	270.26M	220.18M	38.54M	0.00
	Gross Profit
389.86M	362.33M	213.74M	173.21M	29.44M	-3.81M
	EBIT
-15.80M	-45.62M	-25.20M	7.37M	-156.64M	-157.36M
	EBITDA
-14.97M	-45.62M	-22.86M	9.77M	-154.28M	-152.42M
	Net Income Common Stockholders
-16.95M	-43.19M	14.08M	183.36M	-157.92M	-161.38M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
268.34M	243.63M	206.37M	190.61M	182.20M	323.48M
	Total Assets
599.33M	580.55M	526.32M	459.67M	232.80M	349.46M
	Total Debt
9.91M	9.86M	12.26M	5.92M	6.05M	6.99M
	Net Debt
-147.22M	-173.73M	-95.70M	-116.80M	-116.42M	-107.05M
	Total Liabilities
141.84M	142.12M	87.48M	63.52M	47.76M	37.53M
	Stockholders Equity
457.49M	438.44M	438.84M	-492.03M	-675.40M	-517.47M
Cash Flow		Free Cash Flow
43.73M	25.41M	13.17M	5.70M	-146.71M	-136.81M
	Operating Cash Flow
44.03M	25.69M	13.30M	5.81M	-126.30M	-136.53M
	Investing Cash Flow
-39.39M	37.67M	-29.56M	-8.08M	128.63M	-23.44M
	Financing Cash Flow
11.42M	12.27M	1.50M	2.52M	5.88M	227.09M

Kiniksa Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 29.52
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KNSA, the sentiment is Positive. The current price of 29.52 is above the 20-day moving average (MA) of 26.92, above the 50-day MA of 24.20, and above the 200-day MA of 22.90, indicating a bullish trend. The MACD of 1.23 indicates Negative momentum. The RSI at 70.79 is Negative, neither overbought nor oversold. The STOCH value of 86.34 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KNSA.

Kiniksa Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KNSA	75 Outperform	$2.11B	―	-3.81%	―	59.45%	-290.38%
OMCL	67 Neutral	$1.45B	68.86	1.73%	―	3.00%	―
BCRX	66 Neutral	$2.34B	―	18.68%	―	41.67%	75.79%
Sector *	54 Neutral	$5.28B	3.29	-45.38%	2.80%	16.77%	-0.08%
GLPG	53 Neutral	$1.90B	21.22	-6.25%	―	―	―
DVAX	48 Neutral	$1.20B	64.45	-10.45%	―	24.76%	-783.38%
VERA	39 Underperform	$1.97B	―	-39.49%	―	―	-20.03%

Kiniksa Pharmaceuticals Corporate Events

Kiniksa Pharmaceuticals Unveils Phase 2/3 Trial Plans

On June 5, 2025, Kiniksa Pharmaceuticals announced the design and timeline for its Phase 2/3 clinical trial of KPL-387, a monoclonal antibody for treating recurrent pericarditis. The trial is set to begin in mid-2025, with Phase 2 data expected in the second half of 2026. This trial aims to evaluate the efficacy and safety of KPL-387, which is administered subcutaneously, and could potentially expand treatment options for patients with recurrent pericarditis. The announcement underscores Kiniksa’s commitment to advancing its therapeutic options and strengthening its position in the cardiovascular treatment market.

The most recent analyst rating on (KNSA) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Kiniksa Pharmaceuticals stock, see the KNSA Stock Forecast page.

Kiniksa Pharmaceuticals Annual Shareholders Meeting Decisions

On June 3, 2025, Kiniksa Pharmaceuticals held its Annual Meeting of Shareholders where several proposals were voted on and passed. Key decisions included the re-election of directors across three classes, the appointment and remuneration of auditors, and the approval of various financial and governance measures. These resolutions are likely to impact the company’s governance structure and financial operations, potentially influencing its strategic direction and stakeholder relationships.

The most recent analyst rating on (KNSA) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Kiniksa Pharmaceuticals stock, see the KNSA Stock Forecast page.

Kiniksa Pharmaceuticals Approves Long-Term Incentive Plan

On April 17, 2025, Kiniksa Pharmaceuticals‘ Board of Directors approved a Long-Term Incentive Plan for its executive officers, aimed at achieving key milestones related to the development and FDA approval of KPL-387 for recurrent pericarditis. The plan includes cash awards, performance share units, and share options, with the potential for varying earnout percentages based on milestone achievement dates. This initiative reflects Kiniksa’s strategic focus on advancing KPL-387 and incentivizing its leadership to drive the company’s growth and market positioning.